Format

Send to

Choose Destination
J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209.

International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.

Collaborators (192)

Jacobs BC, Hughes RAC, Cornblath DR, Gorson KC, Hartung HP, Kusunoki S, van Doorn PA, Willison HJ, van Woerkom M, van den Berg B, Verboon C, Roodbol J, Jacobs BC, Reisin RC, Reddel SW, Islam Z, Islam B, Mohammad QD, van den Bergh P, Feasby TE, Wang YZ, Harbo T, Péréon Y, Hartung HP, Lehmann HC, Dardiotis E, Nobile-Orazio E, Kusunoki S, Shahrizaila N, Jacobs BC, van den Berg B, Verboon C, Bateman K, Illa I, Querol LA, Hsieh ST, Willison HJ, Chavada G, Davidson A, Gorson KC, Addington JM, Ajroud-Driss S, Andersen H, Antonini G, Attarian S, Badrising U, Barroso FA, Benedetti L, Beronio A, Bianco M, Binda D, Briani C, Bürmann J, Bella IR, Bertorini TE, Bhavaraju-Sanka R, Brannagan TH, Busby M, Butterworth S, Campagnolo M, Casasnovas C, Cavaletti G, Chao CS, Chen S, Chetty S, Claeys KG, Cohen JA, Conti ME, Cosgrove JS, Dalakas MC, Dimachkie MM, Dillmann U, Domínguez González C, Doppler K, Dornonville de la Cour C, Echaniz-Laguna A, Eftimov F, Faber CG, Fazio R, Fokke C, Fujioka T, Fulgenzi EA, Galassi G, Garcia T, Garnero M, Garssen MPJ, Gijsbers CJ, Gilchrist JM, Gilhuis HJ, Goldstein JM, Goyal N, Granit V, Grapperon A, Gutiérrez Gutiérrez G, Gutmann L, Hadden RDM, Holbech JV, Holt JKL, Homedes Pedret C, Htut M, Jellema K, Jericó Pascual I, Kaida K, Karafiath S, Katzberg HD, Kiers L, Kieseier BC, Kimpinski K, Kleyweg RP, Kokubun N, Kolb NA, Kuitwaard K, Kuwabara S, Kwan JY, Ladha SS, Landschoff Lassen L, Lawson V, Ledingham D, Léon Cejas L, Luciano CA, Lucy ST, Lunn MPT, Magot A, Manji H, Marchesoni C, Marfia GAM, Márquez Infante C, Martinez Hernandez E, Mataluni G, Mattiazi M, McDermott CJ, Meekins GD, Miller J, Monges MS, Montero MCJ, Morís de la Tassa G, Nascimbene C, Neumann C, Nowak RJ, Orizaola Balaguer P, Osei-Bonsu M, Pan EBL, Pardo Fernandez J, Pasnoor M, Pulley MT, Rajabally YA, Rinaldi S, Ritter C, Roberts RC, Rojas-Marcos I, Rudnicki SA, Sachs GM, Samijn JPA, Santoro L, Saperstein DS, Savransky A, Schneider H, Schenone A, Sedano Tous MJ, Sekiguchi Y, Sheikh KA, Silvestri NJ, Sindrup SH, Sommer CL, Stein B, Stino AM, Spyropoulos A, Srinivasan J, Suzuki H, Taylor SW, Tankisi H, Tigner D, Twydell PT, Valzania F, van Damme P, van der Kooi AJ, van Dijk GW, van der Ree T, van Koningsveld R, Varrato JD, Vermeij FH, Verschuuren JJGM, Visser LH, Vytopil MV, Waheed W, Wilken M, Wilkerson C, Wirtz PW, Yamagishi Y, Yiu EM, Zhou L, Zivkovic S.

Author information

1
Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
2
Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
3
Department of Neurology, University of Glasgow, Glasgow, Scotland, UK.
4
Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
5
Department of Neurology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA.
6
Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
7
Department of Neurology, University of Düsseldorf, Düsseldorf, Germany.
8
Department of Neurology, Institute of Neurology, University College, London, UK.
9
Department of Neurology, Kinki University School of Medicine, Osaka, Japan.

Abstract

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1-3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01582763.

KEYWORDS:

Guillain-Barré syndrome; biomarkers; diagnosis; outcome; prognosis; treatment

PMID:
28406555
DOI:
10.1111/jns.12209
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center